Furthermore, other Nrf2 agonists, such as bardoxolone methyl, are being evaluated in ongoing clinical trials for kidney disease, including DKD (41), Alport syndrome (AS), and autosomal dominant polycystic kidney disease (ADPKD) (42), providing great therapeutic potential and expectations for the future of Nrf2 agonist development for kidney diseases. This evidence concerns the gene NFE2L2 and diabetic kidney disease.